Adult Heart Failure
At the Forefront of Care for Patients with Worsening Heart Failure: New and Emerging Treatment Options
Supported by an independent medical educational grant from Merck.
Impaired spirometry, COPD raise cardiovascular disease prevalence, incidence
Having impaired vs. normal spirometry findings, as well as COPD, raised the odds for cardiovascular disease and the risk for incident cardiovascular disease, according to study results published in CHEST.
Top in cardiology: Remote ICD deactivation; FDA OKs next-gen cardiovascular CT scanners
A small study suggested that remote deactivation of implantable cardioverter defibrillators in patients receiving hospice care was feasible.
Video: Strict sodium restrictions show no benefit in preventing HF hospitalization
In this video, Anu Lala, MD, associate professor of medicine (cardiology) at Icahn School of Medicine at Mount Sinai, discusses key takeaways from the American College of Cardiology Scientific Session regarding HF.
Empagliflozin safe, effective in HFrEF regardless of systolic BP, NT-proBNP levels
Empagliflozin was safe and effective in patients with HF with reduced ejection fraction regardless of systolic BP or N-terminal pro-B-type natriuretic peptide level, according to two new analyses of results from the EMPEROR-Reduced trial.
Psychoactive substance use disorders rise in patients with HF
From 2008 to 2017, there was a temporal increase in the prevalence of all forms of psychoactive substance use disorders in patients hospitalized for HF, according to research in Circulation: Heart Failure.
Deprescribing CV medications may benefit elderly patients with evolving treatment goals
In recent years, there has been increased emphasis on deprescribing strategies for patients near the end of their lives who are taking a large number of medications, which can be difficult to manage on a day-to-day basis.